[go: up one dir, main page]

BR9303469A - Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas - Google Patents

Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas

Info

Publication number
BR9303469A
BR9303469A BR9303469A BR9303469A BR9303469A BR 9303469 A BR9303469 A BR 9303469A BR 9303469 A BR9303469 A BR 9303469A BR 9303469 A BR9303469 A BR 9303469A BR 9303469 A BR9303469 A BR 9303469A
Authority
BR
Brazil
Prior art keywords
interferon conjugate
preparation
compound
interferon
conjugate
Prior art date
Application number
BR9303469A
Other languages
English (en)
Inventor
Robert Karasiewicz
Carlo Nalin
Perry Rosen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9303469A publication Critical patent/BR9303469A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9303469A 1992-08-26 1993-08-25 Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas BR9303469A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/935,770 US5382657A (en) 1992-08-26 1992-08-26 Peg-interferon conjugates

Publications (1)

Publication Number Publication Date
BR9303469A true BR9303469A (pt) 1994-03-22

Family

ID=25467637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9303469A BR9303469A (pt) 1992-08-26 1993-08-25 Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas

Country Status (37)

Country Link
US (1) US5382657A (pt)
EP (1) EP0593868B1 (pt)
JP (1) JP2859105B2 (pt)
KR (1) KR100295520B1 (pt)
CN (3) CN1183112C (pt)
AT (1) ATE165102T1 (pt)
AU (1) AU668742B2 (pt)
BG (1) BG98067A (pt)
BR (1) BR9303469A (pt)
CA (1) CA2103829C (pt)
CZ (1) CZ169393A3 (pt)
DE (1) DE69317979T2 (pt)
DK (1) DK0593868T3 (pt)
EE (1) EE9400151A (pt)
ES (1) ES2116376T3 (pt)
FI (1) FI109765B (pt)
HR (1) HRP931094A2 (pt)
HU (1) HUT67013A (pt)
IL (1) IL106750A0 (pt)
IS (1) IS4067A (pt)
LT (1) LT3174B (pt)
LV (1) LV10907B (pt)
MW (1) MW7693A1 (pt)
MX (1) MX9305146A (pt)
MY (1) MY131445A (pt)
NO (1) NO933028D0 (pt)
NZ (2) NZ248452A (pt)
OA (1) OA09850A (pt)
PH (1) PH30460A (pt)
PL (1) PL300194A1 (pt)
RO (1) RO112730B1 (pt)
SI (1) SI9300423A (pt)
SK (1) SK89893A3 (pt)
UY (1) UY23635A1 (pt)
YU (1) YU56693A (pt)
ZA (1) ZA936098B (pt)
ZW (1) ZW11193A1 (pt)

Families Citing this family (291)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
AU691225B2 (en) * 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
PT726778E (pt) * 1994-02-08 2001-12-28 Amgen Inc Sistema de administracao oral de proteinas g-csf modificadas quimicamente
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
DE4435087A1 (de) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
WO1997016204A1 (en) 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
WO2000042175A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
TR200000728T2 (tr) * 1997-09-18 2000-09-21 F.Hoffmann-La Roche Ag Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1037649B1 (en) 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
IL138221A0 (en) * 1998-03-26 2001-10-31 Schering Corp Formulations for protection of peg-interferon alpha conjugates
WO1999055377A2 (en) * 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
ATE216591T1 (de) 1998-05-15 2002-05-15 Schering Corp Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
EP1079859B1 (en) * 1998-05-22 2010-07-14 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
IL139786A0 (en) * 1998-06-08 2002-02-10 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
AU773542B2 (en) * 1998-06-16 2004-05-27 Board Of Regents Of The University Of Oklahoma, The Glycosulfopeptides and methods of synthesis and use thereof
US20030143662A1 (en) * 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
EE05111B1 (et) 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
EE05201B1 (et) * 1998-10-16 2009-08-17 Biogen Idec Ma Inc. Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CZ300546B6 (cs) * 1999-01-29 2009-06-10 Amgen, Inc. Fyziologicky aktivní konjugát, prostredek a zpusob prípravy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
PT1535622E (pt) 1999-04-08 2009-03-19 Schering Corp Terapia de melanoma
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
ATE360692T1 (de) 1999-07-07 2007-05-15 Zymogenetics Inc Menschlicher cytokinrezeptor
WO2001005819A1 (en) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6969524B1 (en) 1999-10-12 2005-11-29 Santen Pharamceutical Co., Ltd. Interferon complex and medicinal use thereof
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
EP1231943A1 (en) * 1999-11-12 2002-08-21 Maxygen Holdings Ltd Interferon gamma conjugates
EP1229924A4 (en) 1999-11-19 2004-12-15 Univ Leland Stanford Junior TARGETED BIFUNCTIONAL MOLECULES AND THERAPIES BASED THEREON
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
JP2003534773A (ja) 1999-12-03 2003-11-25 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
MXPA02007172A (es) * 2000-01-24 2002-12-13 Schering Corp Combinacion de temozolomida y alfa interferon pegilado para tratamiento de cancer.
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
CN100488562C (zh) 2000-02-11 2009-05-20 拜耳医药保健有限公司 凝血因子VⅡ或VⅡa样分子
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
AU2001290312A1 (en) * 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
US20030092164A1 (en) 2000-11-07 2003-05-15 Gross Jane A. Human tumor necrosis factor receptor
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
DK1362053T3 (da) * 2001-02-20 2008-03-10 Enzon Inc Terminalt forgrenede polymere linkere og polymere konjugater indeholdende disse
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
CA2439636A1 (en) 2001-03-02 2002-09-12 Zymogenetics, Inc. Mouse cytokine receptor
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
WO2002083166A1 (en) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Interferon-polymer complexes and medicinal use thereof
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
JP4142569B2 (ja) * 2001-06-22 2008-09-03 協和醗酵工業株式会社 軟膏剤
MD2053C2 (ro) * 2001-07-10 2003-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Remediu cu acţiune interferonogenă
ATE376020T1 (de) 2001-08-22 2007-11-15 Bioartificial Gel Technologies Inc Verfahren zu herstellung von aktivierten polyethylenglykolen
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
KR100888371B1 (ko) 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
PL397261A1 (pl) * 2002-01-18 2012-03-26 Biogen Idec Ma Inc. Aktywowany polimer glikolu polialkilenowego, kompozycja i kompozycja farmaceutyczna oraz ich zastosowanie
EP1496076B1 (en) * 2002-03-13 2007-07-25 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
IL164214A0 (en) * 2002-04-11 2005-12-18 Zymogenetics Inc Use of interleukin-24 to treat ovarian cancer
US20040029228A1 (en) 2002-04-19 2004-02-12 Presnell Scott R. Cytokine receptor
PL211175B1 (pl) 2002-06-21 2012-04-30 Novo Nordisk Healthcare Ag Koniugat polipeptydu czynnika VII, sposób wytwarzania takiego koniugatu, zawierający taki koniugat preparat farmaceutyczny oraz zastosowanie takiego koniugatu
EP1539814A2 (en) * 2002-07-03 2005-06-15 Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited Full-length interferon gamma polypeptide variants
RU2318004C2 (ru) * 2002-07-24 2008-02-27 Ф.Хоффманн-Ля Рош Аг Добавки в виде полиалкиленгликолевой кислоты
CN1691956A (zh) * 2002-09-05 2005-11-02 通用医疗公司 去唾液酸干扰素和肝癌的治疗
US20040136955A1 (en) * 2002-09-05 2004-07-15 Barker Nicholas P Modified asialo-interferons and uses thereof
CA2498062C (en) * 2002-09-27 2010-05-25 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor binding protein-4 and poly(ethylene glycol)
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2511814C (en) * 2002-12-26 2015-02-17 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
EP1628618A4 (en) * 2002-12-26 2009-09-09 Mountain View Pharmaceuticals POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY
US7208145B2 (en) * 2002-12-31 2007-04-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
BRPI0407511A (pt) * 2003-02-19 2006-02-14 Pharmacia Corp ésteres de polietilenoglicol ativados
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
DK1668031T3 (da) 2003-08-07 2008-06-30 Zymogenetics Inc Homogene præparater af IL-29
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2005035565A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
ES2398912T3 (es) 2003-10-14 2013-03-22 F. Hoffmann-La Roche Ltd. Ácido carboxílico macrocíclico y compuesto de acilsulfonamida como inhibidor de la replicación del virus de la hepatitis C
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
WO2005042563A2 (en) * 2003-10-22 2005-05-12 Akzo Nobel N.V. Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005062949A2 (en) * 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
JP2007519422A (ja) * 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
RU2311930C2 (ru) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Пэгилированный интерферон для борьбы с вирусной инфекцией
RU2006145020A (ru) * 2004-05-19 2008-06-27 Максиджен, Инк. (Us) Полипептиды и конъюгаты интерферона-альфа
US20060018875A1 (en) * 2004-06-14 2006-01-26 Blatt Lawrence M Interferon compositions and methods of use thereof
BRPI0512235A (pt) * 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
CA2569381A1 (en) * 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP2389944A1 (en) 2004-07-29 2011-11-30 ZymoGenetics, L.L.C. Use of IL-28 and IL-29 to treat cancer
ES2349472T3 (es) 2004-08-12 2011-01-03 Schering Corporation Formulación estable de interferón pegilado.
ES2529451T3 (es) 2004-09-23 2015-02-20 Vasgene Therapeutics, Inc. Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
CN102732588B (zh) * 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
SG160437A1 (en) 2004-12-22 2010-04-29 Ambrx Inc Modified human growth hormone
EP1833993A4 (en) * 2004-12-22 2009-07-22 Ambrx Inc HUMAN GROWTH HORMONE FORMULATIONS COMPRISING AN AMINO ACID CODED NON-NATURALLY
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
CA2596390A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP3214095B1 (en) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
KR20080019619A (ko) * 2005-05-18 2008-03-04 맥시겐, 인크. 개량된 인터페론-알파 폴리펩티드
AU2006255122B2 (en) * 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
AR054778A1 (es) 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
WO2007002233A2 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
EA014157B1 (ru) * 2005-06-29 2010-10-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2)
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
ES2408581T3 (es) * 2005-08-18 2013-06-21 Ambrx, Inc. Composiciones de ARNt y usos de las mismas
DK1931697T3 (da) 2005-09-28 2010-11-08 Zymogenetics Inc IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
JP2009514814A (ja) * 2005-10-21 2009-04-09 シナジェバ・バイオファーマ・コーポレイション グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
SI1954710T1 (sl) * 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
WO2007059312A2 (en) * 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
JP2009519942A (ja) * 2005-12-14 2009-05-21 アンブルックス，インコーポレイテッド 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
KR101418607B1 (ko) 2006-01-12 2014-07-14 호쿠산 가부시키가이샤 인터페론 α를 포함하는 구강 조성물
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US7825152B2 (en) 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
EP2581450B1 (en) * 2006-05-02 2018-08-15 MedImmune Limited Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2029738A2 (en) 2006-05-24 2009-03-04 Novo Nordisk Health Care AG Factor ix analogues having prolonged in vivo half life
US7985734B2 (en) 2006-06-01 2011-07-26 Yun Cheng Peptides for preventing or treating liver damage
CN1911447B (zh) * 2006-06-30 2010-05-12 复旦大学 转铁蛋白-聚乙二醇-药物分子复合物及其制备药物的用途
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP2054076A2 (en) * 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
MX2009002523A (es) * 2006-09-08 2009-03-20 Ambrx Inc Polipeptido de plasma humano modificado o andamios fc y sus usos.
WO2008030614A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
JP5399906B2 (ja) * 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
WO2008066752A2 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R & D Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
JP2010525821A (ja) * 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
CA2698396C (en) 2007-09-04 2014-01-21 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
ATE548382T1 (de) * 2007-09-04 2012-03-15 Biosteed Gene Expression Tech Co Ltd Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
AU2008308509B2 (en) 2007-10-04 2014-10-23 Zymogenetics, Inc. B7 family member zB7H6 and related compositions and methods
CN101918579A (zh) 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
EP2930182A1 (en) * 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
DK2796466T3 (en) 2007-12-07 2018-02-05 Zymogenetics Inc HUMANIZED ANTIBODY MOLECULE SPECIFIC TO IL-31
KR101521674B1 (ko) 2008-04-03 2015-05-19 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 이중-가닥 폴리에틸렌 글리콜-수식된 성장 호르몬, 이의 제조 방법 및 용도
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
WO2009158696A1 (en) 2008-06-27 2009-12-30 Zymogenetics, Inc. SOLUBLE HYBRID Fcγ RECEPTORS AND RELATED METHODS
ES2963062T3 (es) 2008-07-23 2024-03-25 Ambrx Inc Polipéptidos G-CSF bovinos modificados y sus usos
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
NZ592250A (en) 2008-09-26 2012-11-30 Lilly Co Eli Modified animal erythropoietin polypeptides and their uses
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
KR101861295B1 (ko) 2009-06-04 2018-05-25 노파르티스 아게 ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
IN2012MN02896A (pt) 2010-06-24 2015-06-12 Panmed Ltd
UA111065C2 (uk) 2010-07-23 2016-03-25 Демеркс, Інк. Композиції норибогаїну
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SI2605789T1 (sl) 2010-08-17 2019-10-30 Ambrx Inc Modificirani polipeptidi relaksina in njihova uporaba
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
AU2011311706B2 (en) 2010-10-05 2015-11-12 Debiopharm S.A. New treatments of Hepatitis C virus infection
CA2811799A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
EP2646038A1 (en) 2010-11-30 2013-10-09 Novartis AG New treatments of hepatitis c virus infection
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20140018289A1 (en) 2011-03-31 2014-01-16 Novartis Ag New treatments of Hepatitis C virus infection
ES2533213T3 (es) 2011-04-01 2015-04-08 Novartis Ag Tratamiento para infección con el virus de hepatitis B solo o en combinación con el virus de hepatitis Delta y enfermedades hepáticas asociadas
SG10201602184TA (en) 2011-04-13 2016-04-28 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US9422338B2 (en) 2011-05-19 2016-08-23 Epodose Llc Compounds that bind to the erythropoietin receptor
MX2014000031A (es) 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.
US20140314713A1 (en) 2011-07-20 2014-10-23 Universite Paris Diderot - Paris Vii Methods for determining treatment response in patients infected with hcv genotype 4
CN103228792A (zh) * 2011-08-25 2013-07-31 纳诺亘医药生物科技公司 PEG-干扰素λ1结合物
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
KR20140070565A (ko) 2011-09-27 2014-06-10 노파르티스 아게 C형 간염 바이러스 감염의 치료를 위한 알리스포리비르
EP2773659A2 (en) 2011-10-31 2014-09-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9364484B2 (en) 2011-12-06 2016-06-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
EP2830663B1 (en) 2012-03-30 2019-02-06 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013174988A1 (en) 2012-05-24 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
BR112014029883B1 (pt) 2012-05-31 2023-10-24 Sorrento Therapeutics Inc. Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1
DK2859017T3 (da) 2012-06-08 2019-05-13 Sutro Biopharma Inc Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
CA2877573A1 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
CN104981254B (zh) 2012-08-31 2018-05-22 苏特罗生物制药公司 含有叠氮基的经修饰的氨基酸
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
HK1221964A1 (zh) 2013-05-31 2017-06-16 Sorrento Therapeutics, Inc. 与pd-1结合的抗原结合蛋白
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3137078B1 (en) 2014-05-01 2019-03-20 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
EP3180018B1 (en) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
SG11201701382PA (en) 2014-08-22 2017-03-30 Sorrento Therapeutics Inc Antigen binding proteins that bind cxcr3
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
JP6820841B2 (ja) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション ペグ化インターフェロンのための投薬計画
EP3272857B1 (en) * 2015-03-17 2020-08-12 Shigetaka Shimodaira Method for preparing dendritic cell by non-adhesive culture using ifn
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
HK1255463A1 (zh) 2015-11-03 2019-08-16 F. Hoffmann-La Roche Ag Hbv衣壳组装抑制剂和干扰素的组合疗法
EP3370723B1 (en) 2015-11-04 2020-12-16 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
ES2986360T3 (es) 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3570849B1 (en) 2017-01-18 2024-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
HUE065882T2 (hu) 2018-09-11 2024-06-28 Ambrx Inc Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
WO2020068261A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
SG11202108254YA (en) 2019-02-12 2021-08-30 Ambrx Inc Compositions containing, methods and uses of antibody-tlr agonist conjugates
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
US20210285000A1 (en) 2020-03-05 2021-09-16 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CA3174114A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
EP3912627B1 (en) 2020-05-20 2022-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of coronavirus infections
CA3185614A1 (en) 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022043496A2 (en) 2020-08-28 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells as biomarkers and biotargets in covid-19
WO2022079205A1 (en) 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
EP4656202A1 (en) 2023-02-09 2025-12-03 Xie, Yanhui Treatment of atopic dermatitis with polyethylene glycol-modified interleukin 2, glucocorticoid and hyaluronic acid
WO2025006676A2 (en) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651657A (en) * 1949-05-21 1953-09-08 Standard Oil Dev Co Synthetic lubricating oil
SE337223B (pt) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (pt) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (pt) * 1968-07-16
US3632828A (en) * 1968-12-16 1972-01-04 Dow Chemical Co Polyethylene glycol monomethyl ether carbonates
BE758425A (fr) * 1969-12-02 1971-04-16 Baxter Laboratories Inc Streptokinase liee chimiquement a une matrice en carbohydrate (
DE2247163A1 (de) * 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
JPS5470384A (en) * 1977-08-22 1979-06-06 Inst Obu Kiyansaa Risaachi Roi High molecular complex
JPS55110105A (en) * 1979-02-19 1980-08-25 Japan Atom Energy Res Inst Preparation of polymer composition containing physiologically active material
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (ja) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Ｌｐｆ−ｈａの精製法
JPS60127952A (ja) 1983-12-14 1985-07-08 Fanuc Ltd 領域加工方法
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
EP0304311A1 (en) * 1987-08-21 1989-02-22 The Wellcome Foundation Limited Complex of polyethylene glycol and tissue plasminogen activator
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5199360A (en) 1988-09-27 1993-04-06 Sirkka Koistinen Table constructions
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU4660789A (en) * 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2247656T3 (es) * 1989-04-19 2006-03-01 Enzon, Inc. Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno.
EP0400472B1 (en) * 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
JP2978187B2 (ja) * 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 修飾スーパーオキサイドディスムターゼの製造法
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
CA2067224C (en) * 1989-12-01 2001-02-13 Manfred Kurfuerst Hirudin/polyalkylene glycol conjugates
JPH04202293A (ja) * 1990-11-29 1992-07-23 Tonen Corp 作動油
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation

Also Published As

Publication number Publication date
CZ169393A3 (en) 1994-04-13
FI933740L (fi) 1994-02-27
CN1173500A (zh) 1998-02-18
EP0593868A1 (en) 1994-04-27
JPH06192300A (ja) 1994-07-12
LT3174B (en) 1995-02-27
SI9300423A (en) 1994-03-31
ZA936098B (en) 1994-03-01
RO112730B1 (ro) 1997-12-30
OA09850A (fr) 1994-08-15
NZ264872A (en) 1996-01-26
BG98067A (en) 1994-12-02
HU9302366D0 (en) 1993-11-29
IL106750A0 (en) 1993-12-08
HRP931094A2 (en) 1997-06-30
DE69317979T2 (de) 1998-08-20
LTIP888A (lt) 1994-08-25
LV10907B (en) 1996-04-20
SK89893A3 (en) 1994-04-06
ZW11193A1 (en) 1994-03-23
UY23635A1 (es) 1994-03-01
NO933028D0 (no) 1993-08-25
CA2103829A1 (en) 1994-02-27
JP2859105B2 (ja) 1999-02-17
EP0593868B1 (en) 1998-04-15
MW7693A1 (en) 1994-06-08
CN1088936A (zh) 1994-07-06
HUT67013A (en) 1995-01-30
DE69317979D1 (de) 1998-05-20
DK0593868T3 (da) 1999-02-08
YU56693A (sh) 1997-01-08
CA2103829C (en) 2003-04-08
CN1211578A (zh) 1999-03-24
IS4067A (is) 1994-02-27
FI109765B (fi) 2002-10-15
MX9305146A (es) 1994-03-31
US5382657A (en) 1995-01-17
AU668742B2 (en) 1996-05-16
AU4478093A (en) 1994-03-03
LV10907A (lv) 1995-12-20
PH30460A (en) 1997-05-28
EE9400151A (et) 1996-02-15
ATE165102T1 (de) 1998-05-15
MY131445A (en) 2007-08-30
KR940003969A (ko) 1994-03-14
CN1183112C (zh) 2005-01-05
CN1039015C (zh) 1998-07-08
NZ248452A (en) 1995-12-21
ES2116376T3 (es) 1998-07-16
FI933740A0 (fi) 1993-08-25
CN1155618C (zh) 2004-06-30
PL300194A1 (en) 1994-04-05
KR100295520B1 (ko) 2001-09-17

Similar Documents

Publication Publication Date Title
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
BR9201015A (pt) Conjugado de proteina,composto,processo para preparar o conjugado,composicoes farmaceuticas e uso
ATE83374T1 (de) Neue galenische form von fenofibrat.
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
SE8402560L (sv) Farmaceutisk komposition
PT557199E (pt) Conjugados de polietileno glicol hirudina processo de preparacao e uso na cura da trombose
ATE134294T1 (de) Zusammensetzung mit psyllium
ITRM910430A1 (it) Composizioni farmaceutiche di somatostatina con assorbimento migliorato, loro preparazione e loro impiego
IT1190347B (it) Processo per la preparazione dell'n-dimetilchitosano e suoi impieghi farmacologici
IT8748116A0 (it) Derivati di glicina in qualita' di agenti preventivi e terapeutici del le complicanze diabetiche
FI970165A7 (fi) (S)-atenosyyli-L-metioniinin (SAMe) ja sen fysiologisesti hyväksyttävi en suolojen käyttö tilapäisen fokaalisen iskemian aiheuttamien reperfu usiovammojen hoitamiseksi
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
FI933506A7 (fi) Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaat teja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina
RU93050376A (ru) Полиэтилен гликолевые соединения интерферона
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
IT1254452B (it) N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli
IT9021240A0 (it) Composti ad attivita' nootropa, procedimento per la loro preparazione e relative composizioni farmaceutiche
ITRM920930A1 (it) Impiego del glutatione per la preparazione di composizioni farmaceutiche ad attivita' antivirale.
SV1990000045A (es) Preparacion de cicloalcano [b] dehidroindol e-inosulfonamidas sustituidas, ref. le a 27 157-sv.
IT8619899A0 (it) Immino-imidazolidine sostituite, dotate di particolari proprieta'terapeutiche, loro processo di sintensi e composizioni farmaceutiche.
RU92006172A (ru) Фармацевтическая композиция "силокаст" для лечения алопеции
IT8520437A0 (it) Immino-imidazolidine sostituite, dotate di particolari proprieta'terapeutiche loro processo disintesi e composizioni farmaceutiche.
ITMI922216A1 (it) Nitrobenzoilalanine, procedimento per la loro preparazione, loro uso come agenti terapeutici e composizioni farmaceutiche che le contengono
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
KR950700915A (ko) 비사이클로폴리아자매크로사이클로카복실산 착체, 그의 결합체, 그의 제조 방법 및 조영제로서의 그의 용도

Legal Events

Date Code Title Description
EE Request for examination
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal
B15K Others concerning applications: alteration of classification

Ipc: C07D 213/64 (2006.01), A61K 47/60 (2017.0